A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose
escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic
Alopecia (AGA).